Spherix Announces Positive Interim Results In Phase 3 Trial Of Novel, Oral Compound For Type 2 Diabetes
Bethesda, MD /PRNewswire/ — Spherix Incorporated (NASDAQ CM: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced positive interim Phase 3 clinical results for the planned review of the NEET (Naturlose (D-tagatose) Efficacy Evaluation Trial) trial of D-tagatose in drug naïve patients.
Copyright [2009] PR Newswire. All Rights Reserved.
This website uses cookies to ensure you get the best experience on our website. Learn more